Work

724. Phase I Study of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination with Conformal Radiotherapy for the Treatment of Intermediate- to High-Risk Prostate Cancer: Two Year Efficacy Results

Year: 2006

Type: article

Abstract: Adenovirus-mediated suicide gene therapy may hold much promise in the treatment of human cancer. We have developed a novel approach that utilizes an oncolytic, replication-competent adenovirus to deliver a therapeutic CD/HSV-1 TK fusion gene to tumors. The efficacy of oncolytic adenoviral therapy can be enhanced significantly by invoking two suicide gene systems (CD/5-FC and HSV-1 TK/GCV), which render malignant cells sensitive to specific pharmacological agents, and sensitizes them to radiation.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2006.08.804

Authors: Svend O. Freytag, Jae Ho Kim, Hans Stricker, Jan Pegg, Stephen L. Brown, Mei Lu

Institutions: Henry Ford Health, Henry Ford Hospital

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500